The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development.
Publication
, Journal Article
Stockbridge, N; Miller, K; Amur, S; Hillebrenner, M; Zuckerman, B; Fiuzat, M; Califf, RM
Published in: JACC Heart Fail
January 2017
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
January 2017
Volume
5
Issue
1
Start / End Page
67 / 70
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Quality Control
- Humans
- Heart Failure
- Drug Approval
- Cardiovascular Agents
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Stockbridge, N., Miller, K., Amur, S., Hillebrenner, M., Zuckerman, B., Fiuzat, M., & Califf, R. M. (2017). The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development. JACC Heart Fail, 5(1), 67–70. https://doi.org/10.1016/j.jchf.2016.10.009
Stockbridge, Norman, Kristen Miller, Shashi Amur, Matthew Hillebrenner, Bram Zuckerman, Mona Fiuzat, and Robert M. Califf. “The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development.” JACC Heart Fail 5, no. 1 (January 2017): 67–70. https://doi.org/10.1016/j.jchf.2016.10.009.
Stockbridge N, Miller K, Amur S, Hillebrenner M, Zuckerman B, Fiuzat M, et al. The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development. JACC Heart Fail. 2017 Jan;5(1):67–70.
Stockbridge, Norman, et al. “The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development.” JACC Heart Fail, vol. 5, no. 1, Jan. 2017, pp. 67–70. Pubmed, doi:10.1016/j.jchf.2016.10.009.
Stockbridge N, Miller K, Amur S, Hillebrenner M, Zuckerman B, Fiuzat M, Califf RM. The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development. JACC Heart Fail. 2017 Jan;5(1):67–70.
Published In
JACC Heart Fail
DOI
EISSN
2213-1787
Publication Date
January 2017
Volume
5
Issue
1
Start / End Page
67 / 70
Location
United States
Related Subject Headings
- United States Food and Drug Administration
- United States
- Quality Control
- Humans
- Heart Failure
- Drug Approval
- Cardiovascular Agents
- 3201 Cardiovascular medicine and haematology
- 1102 Cardiorespiratory Medicine and Haematology